<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20231025141027&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20231025141027&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 25 Oct 2023 18:10:27 +0000</lastbuilddate>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Regulatory Oversight of Cardiovascular Devices-Why We Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878318/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3903. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878318/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878318</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3903>10.1001/jamacardio.2023.3903</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878318</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Regulatory Oversight of Cardiovascular Devices-Why We Care</dc:title>
<dc:identifier>pmid:37878318</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3903</dc:identifier>
</item>
<item>
<title>Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878306/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The BDP may qualify new, costly devices for higher and automatic Medicare reimbursement despite evidence not being representative of CMS beneficiaries and persistent uncertainty of benefit and risk. To ensure the best evidence is generated to inform clinical care, FDA could apply more selectivity to BDP eligibility, specify objective criteria for revoking Breakthrough designation when appropriate, and ensure timely postmarket evidence generation, whereas CMS could...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3819. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The US Food and Drug Administration (FDA) and Centers for Medicare &amp; Medicaid Services (CMS) have different statutory authorities; FDA evaluates safety and effectiveness for market authorization of medical devices while CMS determines whether coverage is "reasonable and necessary" for its beneficiaries. CMS has recently enacted policies automatically providing supplemental reimbursement for new, costly devices authorized after designation in FDA's Breakthrough Devices Program (BDP) and in June 2023 issued notice for a new Transitional Coverage for Emerging Technologies pathway, accelerating coverage for Breakthrough devices.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: Aiming to incentivize innovation, FDA awards Breakthrough designations early in device development to expedite market authorization and can accept greater uncertainty in benefit and risk, contingent on postmarket evidence generation. Since 2020, Breakthrough designation has effectively automatically qualified devices to receive supplemental Medicare reimbursement after CMS waived a long-standing requirement that devices demonstrate "substantial clinical improvement" for beneficiaries. Using publicly available information, 3 examples of cardiovascular devices illustrate that the BDP may allow for FDA authorization based on less rigorous evidence, such as single-arm trials focused on surrogate end points with short-term follow-up whose participants are often not representative of Medicare beneficiaries. In 1 case, Breakthrough designation allowed a 30% decrease in enrollment of a trial used to support approval. Initial positive findings for some devices have remained unverified, and in 1 case even partially nullified, by postmarket studies. Manufacturers have also used Breakthrough designations to set the price of devices to facilitate additional pass-through payments, leading to higher short-term and long-term costs to CMS and health care systems.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The BDP may qualify new, costly devices for higher and automatic Medicare reimbursement despite evidence not being representative of CMS beneficiaries and persistent uncertainty of benefit and risk. To ensure the best evidence is generated to inform clinical care, FDA could apply more selectivity to BDP eligibility, specify objective criteria for revoking Breakthrough designation when appropriate, and ensure timely postmarket evidence generation, whereas CMS could independently review clinical evidence, advise manufacturers about standards for coverage review, and make supplemental payments and long-term device reimbursement contingent on clinical outcome benefit and postmarket evidence generation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878306/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878306</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3819>10.1001/jamacardio.2023.3819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878306</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Osman Moneer</dc:creator>
<dc:creator>Vinay K Rathi</dc:creator>
<dc:creator>James L Johnston</dc:creator>
<dc:creator>Joseph S Ross</dc:creator>
<dc:creator>Sanket S Dhruva</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program</dc:title>
<dc:identifier>pmid:37878306</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3819</dc:identifier>
</item>
<item>
<title>Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: This study found that viability testing does not identify patients with ischemic cardiomyopathy who benefit from PCI. The extent of nonviable myocardium, but not the extent of viable myocardium, is associated with event-free survival and likelihood of improvement of left ventricular function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3803. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In the Revascularization for Ischemic Ventricular Dysfunction (REVIVED-BCIS2) trial, percutaneous coronary intervention (PCI) did not improve outcomes for patients with ischemic left ventricular dysfunction. Whether myocardial viability testing had prognostic utility for these patients or identified a subpopulation who may benefit from PCI remained unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the effect of the extent of viable and nonviable myocardium on the effectiveness of PCI, prognosis, and improvement in left ventricular function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prospective open-label randomized clinical trial recruiting between August 28, 2013, and March 19, 2020, with a median follow-up of 3.4 years (IQR, 2.3-5.0 years). A total of 40 secondary and tertiary care centers in the United Kingdom were included. Of 700 randomly assigned patients, 610 with left ventricular ejection fraction less than or equal to 35%, extensive coronary artery disease, and evidence of viability in at least 4 myocardial segments that were dysfunctional at rest and who underwent blinded core laboratory viability characterization were included. Data analysis was conducted from March 31, 2022, to May 1, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Percutaneous coronary intervention in addition to optimal medical therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Blinded core laboratory analysis was performed of cardiac magnetic resonance imaging scans and dobutamine stress echocardiograms to quantify the extent of viable and nonviable myocardium, expressed as an absolute percentage of left ventricular mass. The primary outcome of this subgroup analysis was the composite of all-cause death or hospitalization for heart failure. Secondary outcomes were all-cause death, cardiovascular death, hospitalization for heart failure, and improved left ventricular function at 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean (SD) age of the participants was 69.3 (9.0) years. In the PCI group, 258 (87%) were male, and in the optimal medical therapy group, 277 (88%) were male. The primary outcome occurred in 107 of 295 participants assigned to PCI and 114 of 315 participants assigned to optimal medical therapy alone. There was no interaction between the extent of viable or nonviable myocardium and the effect of PCI on the primary or any secondary outcome. Across the study population, the extent of viable myocardium was not associated with the primary outcome (hazard ratio per 10% increase, 0.98; 95% CI, 0.93-1.04) or any secondary outcome. The extent of nonviable myocardium was associated with the primary outcome (hazard ratio, 1.07; 95% CI, 1.00-1.15), all-cause death, cardiovascular death, and improvement in left ventricular function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This study found that viability testing does not identify patients with ischemic cardiomyopathy who benefit from PCI. The extent of nonviable myocardium, but not the extent of viable myocardium, is associated with event-free survival and likelihood of improvement of left ventricular function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01920048.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878295</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3803>10.1001/jamacardio.2023.3803</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878295</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Divaka Perera</dc:creator>
<dc:creator>Matthew Ryan</dc:creator>
<dc:creator>Holly P Morgan</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Matthew Dodd</dc:creator>
<dc:creator>Roshan Weerackody</dc:creator>
<dc:creator>Peter D O'Kane</dc:creator>
<dc:creator>Pier Giorgio Masci</dc:creator>
<dc:creator>Muhummad Sohaib Nazir</dc:creator>
<dc:creator>Alexandros Papachristidis</dc:creator>
<dc:creator>Navtej Chahal</dc:creator>
<dc:creator>Rajdeep Khattar</dc:creator>
<dc:creator>Saad M Ezad</dc:creator>
<dc:creator>Stam Kapetanakis</dc:creator>
<dc:creator>Lana J Dixon</dc:creator>
<dc:creator>Kalpa De Silva</dc:creator>
<dc:creator>Adam K McDiarmid</dc:creator>
<dc:creator>Michael S Marber</dc:creator>
<dc:creator>Theresa McDonagh</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:creator>Tim C Clayton</dc:creator>
<dc:creator>Roxy Senior</dc:creator>
<dc:creator>Amedeo Chiribiri</dc:creator>
<dc:creator>REVIVED-BCIS2 Investigators</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial</dc:title>
<dc:identifier>pmid:37878295</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3803</dc:identifier>
</item>
<item>
<title>Assessment of Myocardial Viability in Ischemic Cardiomyopathy-Scarred by the Data but Still Alive</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3846. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878293</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3846>10.1001/jamacardio.2023.3846</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878293</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Julio A Panza</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Assessment of Myocardial Viability in Ischemic Cardiomyopathy-Scarred by the Data but Still Alive</dc:title>
<dc:identifier>pmid:37878293</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3846</dc:identifier>
</item>
<item>
<title>Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3781. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878289</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3781>10.1001/jamacardio.2023.3781</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878289</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Katherine Anais Sadaniantz</dc:creator>
<dc:creator>Jeffrey A Shih</dc:creator>
<dc:creator>Lara C Kovell</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:37878289</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3781</dc:identifier>
</item>
<item>
<title>Realigning Priorities in the Evaluation and Management of Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3900. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878287</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3900>10.1001/jamacardio.2023.3900</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878287</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>James E Udelson</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Realigning Priorities in the Evaluation and Management of Patients With Heart Failure</dc:title>
<dc:identifier>pmid:37878287</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3900</dc:identifier>
</item>
<item>
<title>Driving Medical Innovation-Focusing on the Evidence to Inform Best Care for Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878282</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3823>10.1001/jamacardio.2023.3823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878282</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Lee A Fleisher</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Driving Medical Innovation-Focusing on the Evidence to Inform Best Care for Patients</dc:title>
<dc:identifier>pmid:37878282</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3823</dc:identifier>
</item>
<item>
<title>Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.3784. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37878275</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3784>10.1001/jamacardio.2023.3784</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878275</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jacob B Pierce</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction-Reply</dc:title>
<dc:identifier>pmid:37878275</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3784</dc:identifier>
</item>
<item>
<title>The Mortality Burden of Untreated Aortic Stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Patients with AS have high mortality risk across all levels of untreated AS severity. Aortic valve replacement rates remain low for patients with severe AS, suggesting that more research is needed to understand barriers to diagnosis and appropriate approach and timing for aortic valve replacement.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 20:S0735-1097(23)07504-6. doi: 10.1016/j.jacc.2023.09.796. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The American College of Cardiology/American Heart Association guidelines recommend the assessment and grading of severity of aortic stenosis (AS) as mild, moderate, or severe, per echocardiogram, and recommend aortic valve replacement (AVR) when the AS is severe.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to describe mortality rates across the entire spectrum of untreated AS from a contemporary, large, real-world database.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed a deidentified real-world data set including 1,669,536 echocardiographic reports (1,085,850 patients) from 24 U.S. hospitals (egnite Database, egnite). Patients >;18 years of age were classified by diagnosed AS severity. Untreated mortality and treatment rates were examined with Kaplan-Meier (KM) estimates, with results compared using the log-rank test. Multivariate hazards analysis was performed to assess associations with all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 595,120 patients with available AS severity assessment, the KM-estimated 4-year unadjusted, untreated, all-cause mortality associated with AS diagnosis of none, mild, mild-to-moderate, moderate, moderate-to-severe, or severe was 13.5% (95% CI: 13.3%-13.7%), 25.0% (95% CI: 23.8%-26.1%), 29.7% (95% CI: 26.8%-32.5%), 33.5% (95% CI: 31.0%-35.8%), 45.7% (95% CI: 37.4%-52.8%), and 44.9% (95% CI: 39.9%-49.6%), respectively. Results were similar when adjusted for informative censoring caused by treatment. KM-estimated 4-year observed treatment rates were 0.2% (95% CI: 0.2%-0.2%), 1.0% (95% CI: 0.7%-1.3%), 4.2% (95% CI: 2.0%-6.3%), 11.4% (95% CI: 9.5%-13.3%), 36.7% (95% CI: 31.8%-41.2%), and 60.7% (95% CI: 58.0%-63.3%), respectively. After adjustment, all degrees of AS severity were associated with increased mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with AS have high mortality risk across all levels of untreated AS severity. Aortic valve replacement rates remain low for patients with severe AS, suggesting that more research is needed to understand barriers to diagnosis and appropriate approach and timing for aortic valve replacement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877909</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.796>10.1016/j.jacc.2023.09.796</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877909</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>Rahul P Sharma</dc:creator>
<dc:creator>Robert J Cubeddu</dc:creator>
<dc:creator>Lucy Aaron</dc:creator>
<dc:creator>Omar M Abdelfattah</dc:creator>
<dc:creator>Konstantinos P Koulogiannis</dc:creator>
<dc:creator>Leo Marcoff</dc:creator>
<dc:creator>Mostafa Naguib</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Rajendra R Makkar</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Benjamin S van Boxtel</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Michael Dobbles</dc:creator>
<dc:creator>Glenn R Barnhart</dc:creator>
<dc:creator>Michelle Kwon</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Linda D Gillam</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Mortality Burden of Untreated Aortic Stenosis</dc:title>
<dc:identifier>pmid:37877909</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.796</dc:identifier>
</item>
<item>
<title>Aortic Stenosis: A 6-Decade Odyssey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07682-9. doi: 10.1016/j.jacc.2023.10.001. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877908</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.001>10.1016/j.jacc.2023.10.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877908</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aortic Stenosis: A 6-Decade Odyssey</dc:title>
<dc:identifier>pmid:37877908</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.001</dc:identifier>
</item>
<item>
<title>4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07628-3. doi: 10.1016/j.jacc.2023.09.813. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877907</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.813>10.1016/j.jacc.2023.09.813</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877907</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>G Michael Deeb</dc:creator>
<dc:creator>Steven J Yakubov</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Mubashir A Mumtaz</dc:creator>
<dc:creator>Basel Ramlawi</dc:creator>
<dc:creator>Tanvir Bajwa</dc:creator>
<dc:creator>Paul S Teirstein</dc:creator>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Jian Huang</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>Evolut Low Risk Trial Investigators</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial</dc:title>
<dc:identifier>pmid:37877907</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.813</dc:identifier>
</item>
<item>
<title>Association of Age and Sex With Use of Transcatheter Aortic Valve Replacement in France</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In France, the use of TAVR remained uncommon in young patients, predominantly restricted to those at high risk. Important sex differences were observed in patent demographics, selection of AVR modality, and patient outcomes. Additional research evaluating the long-term impact of TAVR use in young patients and prospective data evaluating sex differences in AVR modality selection and outcomes are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 11:S0735-1097(23)06649-4. doi: 10.1016/j.jacc.2023.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend selecting surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) based on age, comorbidities, and surgical risk. Nevertheless, reports from the United States suggest a rapid expansion of TAVR in young patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors sought to evaluate the trends in TAVR uptake at a nationwide level in France according to age and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a nationwide administrative database, we evaluated age- and sex-related trends in TAVR uptake, patient demographics, and in-hospital outcomes between 2015 and 2020.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 107,397 patients (44.0% female) underwent an isolated aortic valve replacement (AVR) (59.1% TAVR, 40.9% SAVR). In patients &lt;65 years of age, the proportion of TAVR increased by 63.2% (P &lt; 0.001) from 2015 to 2020 but remained uncommon at 11.1% of all AVR by 2020 (12.4% in females, 10.6% in males) while TAVR was the dominant modality in patients ≥65 years of age. In patients undergoing TAVR, the Charlson comorbidity index (CCI) (P = 0.119 for trend) and in-hospital mortality (P = 0.740 for trend) remained unchanged in patients &lt;65 years of age but declined in those ≥65 years of age irrespective of sex (all P &lt; 0.001 for trends). Females were older (P &lt; 0.001), had lower CCI (P &lt; 0.001), were more likely to undergo TAVR (P &lt; 0.001), and experienced higher in-hospital mortality (TAVR, P = 0.015; SAVR, P &lt; 0.001) that persisted despite adjustment for age and CCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In France, the use of TAVR remained uncommon in young patients, predominantly restricted to those at high risk. Important sex differences were observed in patent demographics, selection of AVR modality, and patient outcomes. Additional research evaluating the long-term impact of TAVR use in young patients and prospective data evaluating sex differences in AVR modality selection and outcomes are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877906</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.044>10.1016/j.jacc.2023.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877906</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Graeme Prosperi-Porta</dc:creator>
<dc:creator>Virginia Nguyen</dc:creator>
<dc:creator>Nadav Willner</dc:creator>
<dc:creator>Julien Dreyfus</dc:creator>
<dc:creator>Helene Eltchaninoff</dc:creator>
<dc:creator>Ian G Burwash</dc:creator>
<dc:creator>Morgane Michel</dc:creator>
<dc:creator>Eric Durand</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Christel Dindorf</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Alain Cribier</dc:creator>
<dc:creator>Alec Vahanian</dc:creator>
<dc:creator>Karine Chevreul</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Age and Sex With Use of Transcatheter Aortic Valve Replacement in France</dc:title>
<dc:identifier>pmid:37877906</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.044</dc:identifier>
</item>
<item>
<title>Adoption of TAVR in Europe vs the United States: Is it Deja-Vù?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 11:S0735-1097(23)06650-0. doi: 10.1016/j.jacc.2023.09.002. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877905</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.002>10.1016/j.jacc.2023.09.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877905</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Antonio Colombo</dc:creator>
<dc:creator>Pier Pasquale Leone</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adoption of TAVR in Europe vs the United States: Is it Deja-Vù?</dc:title>
<dc:identifier>pmid:37877905</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.002</dc:identifier>
</item>
<item>
<title>Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37877288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The PDS was associated with a lower risk of CVD, including CHD and stroke, and a more favorable blood lipid and inflammatory profile, in 3 large prospective cohorts.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 25. doi: 10.1161/CIRCULATIONAHA.123.065551. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The plant-based Portfolio dietary pattern includes recognized cholesterol-lowering foods (ie, plant protein, nuts, viscous fiber, phytosterols, and plant monounsaturated fats) shown to improve several cardiovascular disease (CVD) risk factors in randomized controlled trials. However, there is limited evidence on the role of long-term adherence to the diet and CVD risk. The primary objective was to examine the relationship between the Portfolio Diet Score (PDS) and the risk of total CVD, coronary heart disease (CHD), and stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We prospectively followed 73924 women in the Nurses' Health Study (1984-2016), 92346 women in the Nurses' Health Study II (1991-2017), and 43970 men in the Health Professionals Follow-up Study (1986-2016) without CVD or cancer at baseline. Diet was assessed using validated food frequency questionnaires at baseline and every 4 years using a PDS that positively ranks plant protein (legumes), nuts and seeds, viscous fiber sources, phytosterols (mg/day), and plant monounsaturated fat sources, and negatively ranks foods high in saturated fat and cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During up to 30 years of follow-up, 16917 incident CVD cases, including 10666 CHD cases and 6473 strokes, were documented. After multivariable adjustment for lifestyle factors and a modified Alternate Healthy Eating Index (excluding overlapping components), comparing the highest with the lowest quintile, participants with a higher PDS had a lower risk of total CVD (pooled hazard ratio [HR], 0.86 [95% CI, 0.81-0.92]; <i>P</i><sub>trend</sub> &lt;0.001), CHD (pooled HR, 0.86 [95% CI, 0.80-0.93]; <i>P</i><sub>trend</sub>=0.0001), and stroke (pooled HR, 0.86 [95% CI, 0.78-0.95]; <i>P</i><sub>trend</sub>=0.0003). In addition, a 25-percentile higher PDS was associated with a lower risk of total CVD (pooled HR, 0.92 [95% CI, 0.89-0.95]), CHD (pooled HR, 0.92 [95% CI, 0.88-0.95]), and stroke (pooled HR, 0.92 [95% CI, 0.87-0.96]). Results remained consistent across sensitivity and most subgroup analyses, and there was no evidence of departure from linearity for CVD, CHD, or stroke. In a subset of participants, a higher PDS was associated with a more favorable blood lipid and inflammatory profile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The PDS was associated with a lower risk of CVD, including CHD and stroke, and a more favorable blood lipid and inflammatory profile, in 3 large prospective cohorts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37877288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37877288</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065551>10.1161/CIRCULATIONAHA.123.065551</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37877288</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrea J Glenn</dc:creator>
<dc:creator>Marta Guasch-Ferré</dc:creator>
<dc:creator>Vasanti S Malik</dc:creator>
<dc:creator>Cyril W C Kendall</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Eric B Rimm</dc:creator>
<dc:creator>Walter C Willett</dc:creator>
<dc:creator>Qi Sun</dc:creator>
<dc:creator>David J A Jenkins</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>John L Sievenpiper</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Portfolio Diet Score and Risk of Cardiovascular Disease: Findings From 3 Prospective Cohort Studies</dc:title>
<dc:identifier>pmid:37877288</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065551</dc:identifier>
</item>
<item>
<title>Defining iron deficiency in patients with heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37875635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 24. doi: 10.1038/s41569-023-00951-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37875635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37875635</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00951-6>10.1038/s41569-023-00951-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37875635</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Defining iron deficiency in patients with heart failure</dc:title>
<dc:identifier>pmid:37875635</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00951-6</dc:identifier>
</item>
<item>
<title>Population immunity predicts evolutionary trajectories of SARS-CoV-2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37875109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, and antigenic changes that reduce cross-immunity induced by previous infections or vaccinations. How this functional variation shapes global evolution has remained unclear. Here, we establish a predictive fitness model for SARS-CoV-2 that integrates antigenic and intrinsic selection. The model is informed by tracking of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 11:S0092-8674(23)01076-0. doi: 10.1016/j.cell.2023.09.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, and antigenic changes that reduce cross-immunity induced by previous infections or vaccinations. How this functional variation shapes global evolution has remained unclear. Here, we establish a predictive fitness model for SARS-CoV-2 that integrates antigenic and intrinsic selection. The model is informed by tracking of time-resolved sequence data, epidemiological records, and cross-neutralization data of viral variants. Our inference shows that immune pressure, including contributions of vaccinations and previous infections, has become the dominant force driving the recent evolution of SARS-CoV-2. The fitness model can serve continued surveillance in two ways. First, it successfully predicts the short-term evolution of circulating strains and flags emerging variants likely to displace the previously predominant variant. Second, it predicts likely antigenic profiles of successful escape variants prior to their emergence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37875109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37875109</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.022>10.1016/j.cell.2023.09.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37875109</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Matthijs Meijers</dc:creator>
<dc:creator>Denis Ruchnewitz</dc:creator>
<dc:creator>Jan Eberhardt</dc:creator>
<dc:creator>Marta Łuksza</dc:creator>
<dc:creator>Michael Lässig</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Population immunity predicts evolutionary trajectories of SARS-CoV-2</dc:title>
<dc:identifier>pmid:37875109</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.022</dc:identifier>
</item>
<item>
<title>Human MCTS1-dependent translation of JAK2 is essential for IFN-γ immunity to mycobacteria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37875108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>Human inherited disorders of interferon-gamma (IFN-γ) immunity underlie severe mycobacterial diseases. We report X-linked recessive MCTS1 deficiency in men with mycobacterial disease from kindreds of different ancestries (from China, Finland, Iran, and Saudi Arabia). Complete deficiency of this translation re-initiation factor impairs the translation of a subset of proteins, including the kinase JAK2 in all cell types tested, including T lymphocytes and phagocytes. JAK2 expression is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 18:S0092-8674(23)01078-4. doi: 10.1016/j.cell.2023.09.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human inherited disorders of interferon-gamma (IFN-γ) immunity underlie severe mycobacterial diseases. We report X-linked recessive MCTS1 deficiency in men with mycobacterial disease from kindreds of different ancestries (from China, Finland, Iran, and Saudi Arabia). Complete deficiency of this translation re-initiation factor impairs the translation of a subset of proteins, including the kinase JAK2 in all cell types tested, including T lymphocytes and phagocytes. JAK2 expression is sufficiently low to impair cellular responses to interleukin-23 (IL-23) and partially IL-12, but not other JAK2-dependent cytokines. Defective responses to IL-23 preferentially impair the production of IFN-γ by innate-like adaptive mucosal-associated invariant T cells (MAIT) and γδ T lymphocytes upon mycobacterial challenge. Surprisingly, the lack of MCTS1-dependent translation re-initiation and ribosome recycling seems to be otherwise physiologically redundant in these patients. These findings suggest that X-linked recessive human MCTS1 deficiency underlies isolated mycobacterial disease by impairing JAK2 translation in innate-like adaptive T lymphocytes, thereby impairing the IL-23-dependent induction of IFN-γ.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37875108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37875108</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.024>10.1016/j.cell.2023.09.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37875108</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan Bohlen</dc:creator>
<dc:creator>Qinhua Zhou</dc:creator>
<dc:creator>Quentin Philippot</dc:creator>
<dc:creator>Masato Ogishi</dc:creator>
<dc:creator>Darawan Rinchai</dc:creator>
<dc:creator>Tea Nieminen</dc:creator>
<dc:creator>Simin Seyedpour</dc:creator>
<dc:creator>Nima Parvaneh</dc:creator>
<dc:creator>Nima Rezaei</dc:creator>
<dc:creator>Niloufar Yazdanpanah</dc:creator>
<dc:creator>Mana Momenilandi</dc:creator>
<dc:creator>Clément Conil</dc:creator>
<dc:creator>Anna-Lena Neehus</dc:creator>
<dc:creator>Carltin Schmidt</dc:creator>
<dc:creator>Carlos A Arango-Franco</dc:creator>
<dc:creator>Tom Le Voyer</dc:creator>
<dc:creator>Taushif Khan</dc:creator>
<dc:creator>Rui Yang</dc:creator>
<dc:creator>Julia Puchan</dc:creator>
<dc:creator>Lucia Erazo</dc:creator>
<dc:creator>Mykola Roiuk</dc:creator>
<dc:creator>Taja Vatovec</dc:creator>
<dc:creator>Zarah Janda</dc:creator>
<dc:creator>Ivan Bagarić</dc:creator>
<dc:creator>Marie Materna</dc:creator>
<dc:creator>Adrian Gervais</dc:creator>
<dc:creator>Hailun Li</dc:creator>
<dc:creator>Jérémie Rosain</dc:creator>
<dc:creator>Jessica N Peel</dc:creator>
<dc:creator>Yoann Seeleuthner</dc:creator>
<dc:creator>Ji Eun Han</dc:creator>
<dc:creator>Anne-Sophie L'Honneur</dc:creator>
<dc:creator>Marcela Moncada-Vélez</dc:creator>
<dc:creator>Marta Martin-Fernandez</dc:creator>
<dc:creator>Michael E Horesh</dc:creator>
<dc:creator>Tatiana Kochetkov</dc:creator>
<dc:creator>Monika Schmidt</dc:creator>
<dc:creator>Mohammed A AlShehri</dc:creator>
<dc:creator>Eeva Salo</dc:creator>
<dc:creator>Harri Saxen</dc:creator>
<dc:creator>Gehad ElGhazali</dc:creator>
<dc:creator>Ahmad Yatim</dc:creator>
<dc:creator>Camille Soudée</dc:creator>
<dc:creator>Federica Sallusto</dc:creator>
<dc:creator>Armin Ensser</dc:creator>
<dc:creator>Nico Marr</dc:creator>
<dc:creator>Peng Zhang</dc:creator>
<dc:creator>Dusan Bogunovic</dc:creator>
<dc:creator>Aurélie Cobat</dc:creator>
<dc:creator>Mohammad Shahrooei</dc:creator>
<dc:creator>Vivien Béziat</dc:creator>
<dc:creator>Laurent Abel</dc:creator>
<dc:creator>Xiaochuan Wang</dc:creator>
<dc:creator>Stéphanie Boisson-Dupuis</dc:creator>
<dc:creator>Aurelio A Teleman</dc:creator>
<dc:creator>Jacinta Bustamante</dc:creator>
<dc:creator>Qian Zhang</dc:creator>
<dc:creator>Jean-Laurent Casanova</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human MCTS1-dependent translation of JAK2 is essential for IFN-γ immunity to mycobacteria</dc:title>
<dc:identifier>pmid:37875108</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.024</dc:identifier>
</item>
<item>
<title>One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: a Pre-Specified Analysis of the SWISS-APERO Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37875064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 24. doi: 10.1161/CIRCULATIONAHA.123.067599. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37875064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37875064</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067599>10.1161/CIRCULATIONAHA.123.067599</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37875064</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Roberto Galea</dc:creator>
<dc:creator>Nicolas Meneveau</dc:creator>
<dc:creator>Federico De Marco</dc:creator>
<dc:creator>Adel Aminian</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Konstantina Chalkou</dc:creator>
<dc:creator>Christoph Gräni</dc:creator>
<dc:creator>Frederic Anselme</dc:creator>
<dc:creator>Anna Franzone</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Urs Fischer</dc:creator>
<dc:creator>Francesco Bedogni</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: a Pre-Specified Analysis of the SWISS-APERO Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37875064</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067599</dc:identifier>
</item>
<item>
<title>Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37874971/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Outcomes of SAPIEN 3 TPVI were favourable in patients with CHD, half of whom had native or patched RVOTs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 24:ehad663. doi: 10.1093/eurheartj/ehad663. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related to congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 valve that are insufficiently documented were investigated in the EUROPULMS3 registry of SAPIEN 3-TPVI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patient-related, procedural, and follow-up outcome data were retrospectively assessed in this observational cohort from 35 centres in 15 countries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Data for 840 consecutive patients treated in 2014-2021 at a median age of 29.2 (19.0-41.6) years were obtained. The most common diagnosis was conotruncal defect (70.5%), with a native or patched RVOT in 50.7% of all patients. Valve sizes were 20, 23, 26, and 29 mm in 0.4%, 25.5%, 32.1%, and 42.0% of patients, respectively. Valve implantation was successful in 98.5% [95% confidence interval (CI), 97.4%-99.2%] of patients. Median follow-up was 20.3 (7.1-38.4) months. Eight patients experienced infective endocarditis; 11 required pulmonary valve replacement, with a lower incidence for larger valves (P = .009), and four experienced pulmonary valve thrombosis, including one who died and three who recovered with anticoagulation. Cumulative incidences (95%CI) 1, 3, and 6 years after TPVI were as follows: infective endocarditis, 0.5% (0.0%-1.0%), 0.9% (0.2%-1.6%), and 3.8% (0.0%-8.4%); pulmonary valve replacement, 0.4% (0.0%-0.8%), 1.3% (0.2%-2.4%), and 8.0% (1.2%-14.8%); and pulmonary valve thrombosis, 0.4% (0.0%-0.9%), 0.7% (0.0%-1.3%), and 0.7% (0.0%-1.3%), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Outcomes of SAPIEN 3 TPVI were favourable in patients with CHD, half of whom had native or patched RVOTs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37874971/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37874971</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad663>10.1093/eurheartj/ehad663</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37874971</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sebastien Hascoët</dc:creator>
<dc:creator>James R Bentham</dc:creator>
<dc:creator>Luca Giugno</dc:creator>
<dc:creator>Pedro Betrián-Blasco</dc:creator>
<dc:creator>Aleksander Kempny</dc:creator>
<dc:creator>Ali Houeijeh</dc:creator>
<dc:creator>Haysam Baho</dc:creator>
<dc:creator>Shiv-Raj Sharma</dc:creator>
<dc:creator>Matthew I Jones</dc:creator>
<dc:creator>Elżbieta Katarzyna Biernacka</dc:creator>
<dc:creator>Nicolas Combes</dc:creator>
<dc:creator>Stanimir Georgiev</dc:creator>
<dc:creator>Hélène Bouvaist</dc:creator>
<dc:creator>Jose Diogo Martins</dc:creator>
<dc:creator>Marinos Kantzis</dc:creator>
<dc:creator>Mark Turner</dc:creator>
<dc:creator>Stephan Schubert</dc:creator>
<dc:creator>Zakaria Jalal</dc:creator>
<dc:creator>Gianfranco Butera</dc:creator>
<dc:creator>Sophie Malekzadeh-Milani</dc:creator>
<dc:creator>Estibaliz Valdeolmillos</dc:creator>
<dc:creator>Clement Karsenty</dc:creator>
<dc:creator>Ender Ödemiş</dc:creator>
<dc:creator>Philippe Aldebert</dc:creator>
<dc:creator>Nikolaus A Haas</dc:creator>
<dc:creator>Ihab Khatib</dc:creator>
<dc:creator>Håkan Wåhlander</dc:creator>
<dc:creator>Gianpiero Gaio</dc:creator>
<dc:creator>Alberto Mendoza</dc:creator>
<dc:creator>Sayqa Arif</dc:creator>
<dc:creator>Biagio Castaldi</dc:creator>
<dc:creator>Gaute Dohlen</dc:creator>
<dc:creator>Ronald G Carere</dc:creator>
<dc:creator>Maria Jesus Del Cerro-Marin</dc:creator>
<dc:creator>Erwin Kitzmüller</dc:creator>
<dc:creator>Antony Hermuzi</dc:creator>
<dc:creator>Mario Carminati</dc:creator>
<dc:creator>Patrice Guérin</dc:creator>
<dc:creator>Anja Tengler</dc:creator>
<dc:creator>Alain Fraisse</dc:creator>
<dc:creator>EUROPULMS3 investigators</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry</dc:title>
<dc:identifier>pmid:37874971</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad663</dc:identifier>
</item>
<item>
<title>Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients with Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37874908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 24. doi: 10.1161/CIRCULATIONAHA.123.067312. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices neither in patients with severe AS, nor at the same time as TAVR, has been extensively studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: WATCH-TAVR was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR+LAAO or TAVR+medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR+medical therapy. The primary non-inferiority endpoint was all-cause mortality, stroke, and major bleeding at 2-years between the two strategies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study enrolled 349 patients, 177 TAVR+LAAO and 172 TAVR+medical therapy, between December-2017 and November-2020 at 34 US centers. The mean age was 81 years, CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 4.9 and HAS-BLED score was 3.0. At baseline, 85.4% of patients were taking anticoagulation and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes; the median contrast volume was 119 mL for combined procedures versus 70 mL with TAVR alone. At 24 months follow-up, 82.5% compared to 50.8% of patients were on any antiplatelet therapy, and 13.9% compared to 66.7% of patients were on any anticoagulation therapy in TAVR+LAAO compared to TAVR+medical therapy group respectively. For the composite primary endpoint, TAVR+.LAAO was non-inferior to TAVR+ medical therapy (22.7 vs 27.3 events/100 patient years for TAVR+LAAO and TAVR+medical therapy respectively; Hazard Ratio 0.86, 95% CI 0.60 -1.22, P<sub>noninferiority</sub>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37874908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37874908</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067312>10.1161/CIRCULATIONAHA.123.067312</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37874908</guid>
<pubDate>Tue, 24 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Srinivasa Potluri</dc:creator>
<dc:creator>Vijay Iyer</dc:creator>
<dc:creator>Joseph Aragon</dc:creator>
<dc:creator>Philip Gideon</dc:creator>
<dc:creator>Justin Strote</dc:creator>
<dc:creator>Robert Leonardi</dc:creator>
<dc:creator>Himanshu Agarwal</dc:creator>
<dc:creator>German Larrain</dc:creator>
<dc:creator>Carlos Sanchez</dc:creator>
<dc:creator>Sidakpal S Panaich</dc:creator>
<dc:creator>James Harvey</dc:creator>
<dc:creator>Torsten Vahl</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Qiuqing Wang</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:date>2023-10-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Concomitant Left Atrial Appendage Occlusion and Transcatheter Aortic Valve Replacement Among Patients with Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37874908</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067312</dc:identifier>
</item>
<item>
<title>Risk Factors for Reintervention With Functionally Single-Ventricle Disease Undergoing Staged Palliation in England and Wales: A Retrospective Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37871240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231025141027&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 24;148(17):1343-1345. doi: 10.1161/CIRCULATIONAHA.123.065647. Epub 2023 Oct 23.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37871240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">37871240</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10589421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231025141027&v=2.17.9.post6+86293ac">PMC10589421</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065647>10.1161/CIRCULATIONAHA.123.065647</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37871240</guid>
<pubDate>Mon, 23 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Qi Huang</dc:creator>
<dc:creator>Deborah Ridout</dc:creator>
<dc:creator>Victor Tsang</dc:creator>
<dc:creator>Nigel E Drury</dc:creator>
<dc:creator>Timothy J Jones</dc:creator>
<dc:creator>Hannah Bellsham-Revell</dc:creator>
<dc:creator>Elena Hadjicosta</dc:creator>
<dc:creator>Anna N Seale</dc:creator>
<dc:creator>Chetan Mehta</dc:creator>
<dc:creator>Christina Pagel</dc:creator>
<dc:creator>Sonya Crowe</dc:creator>
<dc:creator>Ferran Espuny-Pujol</dc:creator>
<dc:creator>Rodney C G Franklin</dc:creator>
<dc:creator>Kate L Brown</dc:creator>
<dc:date>2023-10-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk Factors for Reintervention With Functionally Single-Ventricle Disease Undergoing Staged Palliation in England and Wales: A Retrospective Cohort Study</dc:title>
<dc:identifier>pmid:37871240</dc:identifier>
<dc:identifier>pmc:PMC10589421</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065647</dc:identifier>
</item>





























</channel>
</rss>